Recombinant Adenovirus Vector Vaccine Studies

$0Z01FY2006AINIH

Niaid Extramural Activities

Investigators

Linked publications & trials

Paper 19420074 Paper 18987146 Paper 18586707 Paper 18369434 Paper 17319743 Paper 17250935 Paper 17224918 Paper 16763152 Paper 16735692 Paper 16622001 Paper 16597342 Paper 15956548 Paper 15858035 Paper 15761255 Paper 15613305 Paper 15128818 Paper 12941918

Abstract

Adenovirus vectors have shown promise for vaccines, but one key hurdle is preexisting immunity to these viruses in humans. The VRC has been investigating the use of DNA priming and the use of alternate adenoviral serotypes or modified adenoviral vectors to overcome prior immunity. During the past year, the VRC has evaluated various modifications to Adenovirus serotype 5 and 35 vectors to determine if they remain immunogenic while reducing the impact of prior exposure to Ad5.

View original record on NIH RePORTER →